Chromosome 18 Clinical Research Center

Learn more about:
Related Clinical Trial
Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy Impact of GH Measurements on GHD Diagnosis Fluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation Test Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™ The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents Constructing an Insulin-Like Growth Factor-based Prediction Model Peripheral Metabolic Effects of Somatostatin Chromosome 18 Clinical Research Center The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids. An Observational Study on Treatment Compliance by Children Treated With Growth Hormone A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters) A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Safety and Efficacy of Long-term Somatropin Treatment in Adults Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle Genotropin Study Assessing Use of Injection Pen Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy Treatment of Children With Insufficient Secretion of Growth Hormone Metabolic and QOL Effects of GH Treatment in Patients With TBI and AGHD Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA) Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Inter-Assay Growth Hormone and IGF-I Variability A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy Easypod United States User Trial National Cooperative Growth Study in CKD Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients Practicability and Acceptability of Stylomax® in Children Growth Hormone’s Effect on the Cardiovascular System Exploring Interactions Between Growth Hormone and the Microbiome Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children Phase 1 Safety Study of ALRN-5281 in Healthy Subjects Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Growth Hormone and Chromosome 18q- and Abnormal Growth An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin® Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Study of TV-1106 in Growth Hormone-Deficient Adults Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates Gene Expression in Monocytes of Growth Hormone Deficient Children Study of Pituitary Size and Function in Familial Dwarfism of Sindh Adipocyte Function and Somtropin Deficiency Sustained Release Formulation of Somatropin (rDNA Origin)for Injection Molecular Basis of the Growth Axis in Short Stature Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States The Effects of Growth Hormone (GH) on Lipid Depots The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study Effects of Growth Hormone Supplementation to Adults With Growth Hormone Deficient on Metabolism and Adipose Tissue Molecular Phenotype Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing Metabolic Endocrinology and Growth Hormone in Adults Growth Hormone Treatment of Young Growth Hormone-Deficient Adults Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) rhGH Therapy on Hepatic Drug Metabolism Skeletal Muscle Effects of GH in Boys Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas Adipose Tissue and Serum Inflammation in GH Deficiency Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

Brief Title

Chromosome 18 Clinical Research Center

Official Title

The Chromosome 18 Clinical Research Center

Brief Summary

      Our vision, that of the researchers at the University of Texas Health Science Center at San
      Antonio, is that every person with a chromosome 18 abnormality will have an autonomous and
      healthy life. Our mission is to provide families affected by chromosome 18 abnormalities with
      comprehensive medical and educational information. Our goals are to provide definitive
      medical and education resources for the families of individuals with chromosome 18
      abnormalities; perform and facilitate groundbreaking clinical and basic research relating to
      the syndromes of chromosome 18; and to provide treatments to help these individuals overcome
      the effects of their chromosome abnormality.
    

Detailed Description

      Protocol Summary:

      The hypotheses are:

        1. growth hormone (GH) deficiency in children with chromosome 18 deletions is accompanied
           by cognitive and microstructural abnormalities of the brain that can be ameliorated by
           GH treatment; and

        2. the physical and behavioral findings in individuals with abnormalities of chromosome 18
           are due to the genes that present in a non-diploid number.

      Therefore, correlation of the physical and behavioral findings with the extent of the
      deletion will help identify the genes involved. An understanding of the molecular mechanisms
      of the phenotype will provide the insight necessary to devise appropriate therapies.

      Our goals are:

        1. to be the international medical and education resource for the families of individuals
           with chromosome 18 abnormalities;

        2. to perform and facilitate both clinical and basic research relating to the disorders of
           chromosome 18; and

        3. to devise treatments to help these individuals overcome the negative effects of their
           chromosome abnormality.

      To attain these goals, the study has the following specific aims:

        1. perform genotypic molecular analysis on the DNA of the subjects and their biological
           parents to determine the genotype of the affected individual;

        2. gather comprehensive clinical data on individuals with chromosome 18 abnormalities
           including:

             1. determination of growth hormone levels;

             2. measurement of corticotrophin, thyroid and sex hormones;

             3. psychiatric and neuropsychological evaluations;

             4. audiology and ENT testing;

             5. brain MRI scan;

             6. genetic dysmorphology examination;

             7. neurology exam;

             8. dental exam;

             9. speech pathology evaluation;

            10. gastrointestinal exam;

            11. orthopedic exam;

            12. ophthalmology exam.

      The phenotypical assessment will be longitudinal; therefore, the participants will have a
      wide age range. This extensive range plus the fact that some participants will be assessed
      multiple times means that not all components of the clinical studies will be appropriate for
      every subject at every visit.
    


Study Type

Observational


Primary Outcome

Primary


Condition

Chromosome Aberrations

Intervention

Determination of growth hormone status


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Procedure

Estimated Enrollment

4000

Start Date

September 1993

Completion Date

December 2040

Primary Completion Date

December 2040

Eligibility Criteria

        Inclusion Criteria:

          -  Must have a confirmed diagnosis of Chromosome 18 or be the parent/guardian of a child
             with Chromosome 18

          -  Subject must be at least one year of age to participate in the clinical examination
             aspect of the study (due to issues of venous access and blood volume required to
             complete studies)

          -  General health status: good

        Exclusion Criteria:

          -  Pregnant women

          -  Dead fetuses

          -  Prisoners

          -  Non-viable neonates or neonates of uncertain viability
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Jannine D. Cody, Ph.D., 210-567-9220, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00227253

Organization ID

Chromosome 18

Secondary IDs

IRB: 990-9000-318

Responsible Party

Sponsor

Study Sponsor

The University of Texas Health Science Center at San Antonio


Study Sponsor

Jannine D. Cody, Ph.D., Principal Investigator, The University of Texas Health Science Center at San Antonio


Verification Date

October 2021